Αρχική World News Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with... World News Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma Από Ogkologos - 24 Φεβρουαρίου, 2026 419 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... 19 Μαΐου, 2021 Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? 11 Οκτωβρίου, 2024 Healthy and Delicious Figs 10 Σεπτεμβρίου, 2021 Seeing a Promising Future for Progress against Childhood Cancer 16 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information Foodie Friday: Winter Warm-Up White Bean Soup